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OBJECTIVES We sought to determine predictors for adverse outcomes in hypertensive patients with
coronary artery disease (CAD).
BACKGROUND Factors leading to adverse outcomes in hypertensive patients with CAD are poorly
understood. The INternational VErapamil-trandolapril STudy (INVEST) compared out-
comes in hypertensive patients with CAD that were assigned randomly to either a verapamil
sustained-release (SR)- or an atenolol-based strategy for blood pressure (BP) control.
Trandolapril and hydrochlorothiazide were used as added agents. During follow-up (61,835
patient-years), BP control and the primary outcome (death, nonfatal myocardial infarction,
and nonfatal stroke) were not different between strategies.
METHODS We investigated risk for adverse outcome associated with baseline factors, follow-up BP, and
drug treatments using Cox modeling.
RESULTS Previous heart failure (adjusted hazard ratio [HR] 1.96), as well as diabetes (HR 1.77),
increased age (HR 1.63), U.S. residency (HR 1.61), renal impairment (HR 1.50), stroke/
transient ischemic attack (HR 1.43), smoking (HR 1.41), myocardial infarction (HR 1.34),
peripheral vascular disease (HR 1.27), and revascularization (HR 1.15) predicted increased
risk. Follow-up systolic BP 140 mm Hg or diastolic BP 90 mm Hg (HRs 0.82 or 0.70,
respectively) and trandolapril with verapamil SR (HRs 0.78 and 0.79) were associated with
reduced risk.
CONCLUSIONS In hypertensive patients with CAD, increased risk for adverse outcomes was associated with
conditions related to the severity of CAD and diminished left ventricular function. Lower
follow-up BP and addition of trandolapril to verapamil SR each were associated with reduced
risk. (J Am Coll Cardiol 2006;47:547–51) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.031Foundation
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ehe management of blood pressure (BP) in patients with
oronary artery disease (CAD) remains a challenge; as the
opulation ages, more patients survive myocardial infarction
MI), and the prevalence of diabetes, obesity, and inactivity
ncreases (1). To better manage these patients, more pro-
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Predictors of Adverse Outcome February 7, 2006:547–51ibitors, and organ protection; enrolled few patients with
AD; and many had inadequate BP control (2). Calcium
ntagonists and angiotensin-converting enzyme inhibitors
educe events; however, their value compared with beta-
locker/diuretic treatment has not been sufficiently tested in
ontemporary hypertensive patients with CAD. The fore-
oing provided rationale for the INternational VErapamil-
randolapril STudy (INVEST) and for this prespecified
nalysis to investigate factors leading to risk for adverse
utcomes.
ETHODS
verview. Beginning in 1997, the INVEST randomly
ssigned 22,576 CAD patients 50 years or older to either a
erapamil sustained-release (SR)-based or an atenolol-based
trategy for BP control. After an extensive cardiovascular
istory and physical examination, multidrug treatment
trategies were titrated to BP 140/90 mm Hg, or
130/85 mm Hg for diabetes or renal impairment (3).
igure 1. Predictors of increased risk (adjusted hazard ratio [HR] and 95%
Abbreviations and Acronyms
BMI  body mass index
BP  blood pressure
CAD  coronary artery disease
CI  confidence interval
DBP  diastolic blood pressure
HCTZ  hydrochlorothiazide
HR  hazard ratio
INVEST  INternational VErapamil-trandolapril STudy
MI  myocardial infarction
SBP  systolic blood pressure
SR  sustained releaseVD  peripheral vascular disease; TIA  transient ischemic attack. *Covariate
p  0.05; §coronary bypass/percutaneous coronary intervention.randolapril and hydrochlorothiazide (HCTZ) were spec-
fied as added agents, with trandolapril primary in the
erapamil SR strategy and HCTZ primary in the atenolol
trategy. In both strategies, trandolapril was recommended
or heart failure, diabetes, or renal impairment. The trial
oncluded in 2003, accumulating 61,835 patient-years
ollow-up. Each strategy provided excellent BP control
70% of patients achieved BP 140/90 mm Hg) and the
trategies were equivalent in preventing all-cause death,
onfatal MI, or nonfatal stroke (primary outcome). The
esign and results have been published (4,5).
ata analysis. To identify factors associated with risk for
rimary outcome, stepwise Cox proportional-hazards re-
ression was used to provide hazard ratios (HRs) and 95%
onfidence intervals (CIs) for the following baseline covari-
tes: age (10-year increments), gender, race/ethnicity (Cau-
asian, Asian, black, Hispanic, multiracial/other), U.S. res-
dency, body mass index (BMI) in 5-kg/m2 increments, MI,
eart failure (functional class I to III), renal impairment,
eripheral vascular disease, aspirin use, left ventricular
ypertrophy, smoking (ever), coronary revascularization,
troke/transient ischemic attack, angina pectoris, unstable
ngina, arrhythmia, hypercholesterolemia, and diabetes.
respecified covariates (age, gender, race/ethnicity, previous
I, and heart failure), as well as a factor for strategy were
orced entries. The remaining covariates were selected by
he procedure and retained when p  0.1.
Baseline systolic blood pressure (SBP) and diastolic blood
ressure (DBP) were assessed by adding these terms to the
forementioned Cox model. To assess the effect of BP after
andomization, we used exploratory Cox regression models
xcluding treatment strategy both unadjusted and stepwise
ence interval [CI]) for the primary outcome. MI myocardial infarction;confid
s forced into Cox model; other covariates selected at p  0.1; †p  0.001;
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February 7, 2006:547–51 Predictors of Adverse Outcomeith BP fit as a time-dependent variable. Here, patients
ere categorized by SBP 140 mm Hg or 140 mm Hg
nd DBP 90 mm Hg or 90 mm Hg at each visit.
dditionally, a model with terms for baseline covariate,
ime-dependent SBP category (more than six weeks prior to
rimary outcome event or censoring) and the interaction
erm was used to assess the effect of the prognostic factors
n primary outcome.
A further model used average daily dose of each strategy
rug for each patient and variables indicating the proportion
f verapamil SR and trandolapril, or the proportion of
tenolol and HCTZ, prescribed simultaneously in addition
o treatment strategy; interactions of drug-dose variables
ith strategy; and prespecified baseline covariates to assess
he relationship between study drugs and primary outcome
6). Drug-dose variables were fit as time-dependent. Esti-
ates are presented for selected dose combinations assum-
ng simultaneous proportions are 100%, with atenolol 50
g/day as the reference (HR  1.0).igure 2. Risk (adjusted hazard ratio [HR] and 95% confidence interval [CI]) fo
ystolic blood pressure (SBP) category. In general, risk was lower when SBP wMean and standard deviation were provided for contin-
ous variables, or number of patients and percent (%) for
ategorical variables. Statistical significance was assumed if
 0.05 (two-tailed).
ESULTS
onditions associated with increased risk. Baseline con-
itions independently associated with increased risk along
ith HRs and 95% CIs appear in Figure 1. Adjusted risk for
he primary outcome was highest for patients with previous
eart failure or diabetes. Interestingly, black race was not
ssociated with significant increase in risk, whereas His-
anic and Asian race were associated with benefit. After
djusting for these baseline conditions, there was still no
ifference in risk comparing the verapamil SR and atenolol
trategies (HR 0.97, 95% CI 0.89 to 1.05).
nfluence of BP. Baseline SBP and DBP demonstrated no
ssociation with risk for the primary outcome, either with or
ithout adjustment. Lower on-treatment BP was associatedr primary outcome associated with high-risk subgroups by time-dependent
as 140 mm Hg. See Figure 1 for definitions.
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Predictors of Adverse Outcome February 7, 2006:547–51ith benefit (SBP 140 mm Hg or DBP 90 mm Hg,
nadjusted HR  0.73, p  0.001, adjusted HR  0.82, p
0.001 or unadjusted HR 0.91, p 0.136; adjusted HR
0.70, p  0.001, respectively). Similar results were
bserved in high-risk subgroups (Fig. 2).
nfluence of antihypertensive drugs. On-treatment mean
Ps and proportions of patients with SBP 140 mm Hg
ere very comparable between patients receiving mono-
herapies and those receiving multiple drugs. At month 24
or those receiving verapamil alone, those values were 127.2
m Hg, 87.8%; atenolol alone, 127.2 mm Hg, 85.8%; and
ual therapies, verapamil  trandolapril, 129.3 mm Hg,
0.1% and atenolol  HCTZ, 129.6 mm Hg, 78.9%.
At these comparable BPs, exploratory drug-dose model-
ng using selected doses suggested that added drugs were
ssociated with additional benefits (Fig. 3). Although some
ombinations of verapamil SR and trandolapril (180 mg/2
g/day) showed significant risk reduction, all multidrug
ombinations showed trends for benefit compared with
tenolol 50 mg/day alone.
ISCUSSION
revious studies have identified factors associated with
dverse outcomes in populations with or at high risk for
AD, but reports that focus on hypertensive patients with
AD are limited. Thus these observations extend previous
ndings to older patients with CAD using contemporary
igure 3. Risk (hazard ratios [HRs] and 95% confidence intervals [CIs])
trategy was not a predictor of risk (Fig. 1). Selected doses of verapamil
ombinations showed beneficial trends compared with monotherapy. Referugs for hypertension. For example, in patients with CAD iho had lower-extremity arterial disease, predictors of
ortality included increased age, CAD severity/extent,
iminished left ventricular function, hypertension, smoking,
nd diabetes (7). More recently, in hypertensive patients at
igh risk for CAD, age, left ventricular hypertrophy, dia-
etes, and average SBP during follow-up were independent
redictors of risk (8). We found in hypertensive patients
ith CAD that factors related to heart failure and CAD
everity (e.g., diabetes, increased age renal impairment,
troke/transient attack, smoking, MI, peripheral vascular
isease, and coronary revascularization) were all indepen-
ently associated with increased risk for death, MI, or
troke. Of clinical interest, exploratory analyses indicated
hat achieving SBP 140 mm Hg and receiving combina-
ion drug therapy each mitigate some of that risk (Figs. 2
nd 3). Because CAD is both disabling and associated with
ubsequent morbidity and mortality, these findings identify
large group of patients for whom even closer continuing
are and more intense therapy may be warranted.
Association between higher BP and increased risk is well
stablished but has not been emphasized for elderly hyper-
ensive patients with CAD. In general, we found in explor-
tory analyses that time-dependent SBP 140 mm Hg was
ssociated with lower risk, in both the low- and high-risk
ubgroups defined by baseline conditions (Fig. 2).
When BP is reduced to comparable levels by different
rugs, especially in patients with the high-risk conditions
rimary outcome by strategy drugs and drug dose. Randomized treatment
ined released (SR) plus trandolapril were statistically significant, but all
is atenolol 50 mg/day. HCTZ  hydrochlorothiazide.for pdentified here, the choice of antihypertensive agents may be
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February 7, 2006:547–51 Predictors of Adverse Outcomemportant in further reducing risk. Of current interest was
he finding that trends to reduce risk appeared for addition
f HCTZ to atenolol and trandolapril to verapamil SR.
owever, adding trandolapril to verapamil SR was associ-
ted with significant risk reduction at certain doses, with
nd without addition of HCTZ. This finding is consistent
ith results of other trials in high-risk patients (2,9,10).
eneficial trends occurred at all doses of trandolapril, and
isk reduction was significant for the 2-mg dose when added
o verapamil, despite the fact that trandolapril also was
ecommended for diabetes, heart failure, or renal impair-
ent in the atenolol strategy. These results should be
iewed as support for a multi-drug BP control strategy that
ncludes angiotensin-converting enzyme inhibition in high-
isk patients with CAD.
tudy limitations. Patients younger than 50 years of age,
hose with functional class IV heart failure, with creatinine
evels 4.0 mg/dl, or recent stroke, unstable angina, coro-
ary revascularization, or MI were excluded. Surprisingly,
ncreased BMI was not associated with increased risk, but
hese findings require additional analysis beyond the scope
f this publication. Interactions with age, smoking, gender,
nd disease and, particularly, the increase in all cause
ortality observed among those with lower BMI in large
dult cohorts (11) make this analysis complex. Yet the
ossibility remains that when BP is well controlled and
rgan protection is implemented for heart failure, diabetes,
nd renal impairment, increased BMI could have less of an
mpact on outcomes. Because drugs and doses given were
ependent on BP response and other factors (e.g., patient’s
ell-being), some confounding is unavoidable. Finally, ef-
ects of nonstrategy antihypertensive drugs were not ana-
yzed; however, sensitivity analyses indicated they did not
lter results qualitatively.
onclusions. Many conditions in hypertensive patients
ith CAD impart excess risk. Age, as well as previous
iabetes, stroke/transient ischemic attack, smoking, heart
ailure, renal impairment, MI, peripheral vascular disease,
nd revascularization are independently associated with
ncreased risk. In general, the high risk associated with these
onditions was reduced by achieving a SBP 140 mm Hg.
lthough both treatment strategies provided excellent BP
ontrol, with no difference in outcomes overall, the additionion in risk, and this combination may offer greater protec-
ion than monotherapy. Although all patients with CAD
nd hypertension require aggressive risk factor modification,
he subgroup with these risk conditions may benefit from
articularly close surveillance for residual BP elevation and
onsideration for additional therapies.
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